MannKind is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's product, Afrezza (insulin human) Inhalation Powder, is an inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a portable inhaler.

scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs. The company's proprietary platform is designed to enable the subcutaneous administration of therapies that have previously been limited to intravenous delivery. The company's primary product candidate, FUROSCIX, consists of the company's buffered formulation of furosemide delivered subcutaneously via an on-body infusor and is under development for treatment of congestion in patients with worsening heart failure who display reduced responsiveness to oral diuretics and do not require hospitalization.